EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects

Ying Yang, Mai Han, Gang Cui, Dan Zhang, Wei Wu, Na Mi, Jiangli Jin, Shuxiao Zhang, Xin Zhang, Junjie Li, Chunyan Xiao, Jing Wang und 3 weitere

Pharmacology Research & Perspectives · 2026-06 · 14 (3)

DOI: 10.1002/prp2.70277 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 15.06.2026. Verfasst von Ying Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Joincare Pharmaceutical Group Industry Co., Ltd., Shenzhen, China. Hauptthemen laut MEDLINE: NAV1.8 Voltage-Gated Sodium Channel, Voltage-Gated Sodium Channel Blockers. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first‐in‐human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE). This was a single center, randomized, double‐blind, placebo controlled, single ascending dose (SAD) and FEstudy in healthy Chinese subjects. In the SAD part, 44 subjects were randomized to receive a single oral dose of JKN2306 (10, 30, 100, 200, or 400 mg) or placebo. The FE part was a sequential, two‐period crossover study in 14 subjects from the 200 mg SAD cohort, who received a single 200 mg dose under fasting and fed conditions. Forty‐four subjects were enrolled and completed the study. JKN2306 was safe and well‐tolerated across all doses. Treatment‐emergent adverse events were mostly Grade 1, with no serious adverse events or dose limiting toxicities. No clinically significant effects on QTc interval were observed. JKN2306 was rapidly absorbed, with T max of 1.50–2.50 h. The t 1/2 ranged from 13.93 to 29.82 h. Exposure ( C max and AUC) increased approximately linearly with dose over the 10–400 mg range. Food intake delayed the median T max by 1 h and reduced C max by about 17%, but had no significant effect on AUC. JKN2306 exhibits a favorable safety and tolerability profile and predictable linear PK in healthy subjects. Food has a modest effect on the rate but not the extent of absorption. These findings support the further clinical development of JKN2306 for the treatment of acute pain. Trial Registration: chinadrugtrials.org.cn identifier: CTR20250247 and clinicaltrials.gov identifier: NCT07412938

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.8 Voltage-Gated Sodium ChannelVoltage-Gated Sodium Channel BlockersAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFood-Drug InteractionsHealthy VolunteersEast Asian People

Stichwörter der Autor:innen

JKN2306NaV1.8 inhibitorfood effectpharmacokineticssafety

Substanzen

NAV1.8 Voltage-Gated Sodium ChannelVoltage-Gated Sodium Channel Blockers

Autor:innen und Institutionen

  • Joincare Pharmaceutical Group Industry Co., Ltd., Shenzhen, China.
  • Drug Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, China.

ORCID-Profile: Chong Su

Zitieren

APA

Yang, Y., Han, M., Cui, G., Zhang, D., Wu, W., Mi, N., Jin, J., Zhang, S., Zhang, X., Li, J., Xiao, C., Wang, J., Gou, C., Su, C., & Li, J. (2026). A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70277

Vancouver

Yang Y, Han M, Cui G, Zhang D, Wu W, Mi N, et al. A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70277

BibTeX
@article{Yang2026,
  author = {Yang, Ying and Han, Mai and Cui, Gang and Zhang, Dan and Wu, Wei and Mi, Na and Jin, Jiangli and Zhang, Shuxiao and Zhang, Xin and Li, Junjie and Xiao, Chunyan and Wang, Jing and Gou, Chaoyun and Su, Chong and Li, Jintong},
  title = {A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/prp2.70277}
}
Kostenlos starten →